Miriam Mattoscio1, Richard Nicholas1, Maria P Sormani1, Omar Malik1, Jean S Lee1, Adam D Waldman1, Francesco Dazzi1, Paolo A Muraro2. 1. From the Department of Medicine, Division of Brain Sciences, Centre for Neuroscience, Wolfson Neuroscience Laboratories (M.M., R.N., O.M., P.A.M.), and the Department of Medicine, Division of Experimental Medicine, Centre for Haematology (F.D.), Imperial College London, UK; the Departments of Neurosciences (R.N., O.M.) and Imaging (J.S.L., A.D.W.), Imperial College Healthcare NHS Trust, London, UK; and the Biostatistics Unit, Department of Health Sciences (M.P.S.), University of Genoa, Italy. 2. From the Department of Medicine, Division of Brain Sciences, Centre for Neuroscience, Wolfson Neuroscience Laboratories (M.M., R.N., O.M., P.A.M.), and the Department of Medicine, Division of Experimental Medicine, Centre for Haematology (F.D.), Imperial College London, UK; the Departments of Neurosciences (R.N., O.M.) and Imaging (J.S.L., A.D.W.), Imperial College Healthcare NHS Trust, London, UK; and the Biostatistics Unit, Department of Health Sciences (M.P.S.), University of Genoa, Italy. p.muraro@imperial.ac.uk.
Abstract
OBJECTIVE: To ascertain the mobilization from the bone marrow and the functional relevance of the increased number of circulating hematopoietic stem and progenitor cells (HSPC) induced by the anti-α-4 integrin antibody natalizumab in patients with multiple sclerosis (MS). METHODS: We evaluated CD45(low)CD34+ HSPC frequency by flow cytometry in blood from 45 natalizumab-treated patients (12 of whom were prospectively followed during the first year of treatment as part of a pilot cohort and 16 prospectively followed for validation), 10 untreated patients with MS, and 24 healthy donors. In the natalizumab-treated group, we also assessed sorted HSPC cell cycle status, T- and B-lymphocyte subpopulation frequencies (n = 29), and HSPC differentiation potential (n = 10). RESULTS: Natalizumab-induced circulating HSPC were predominantly quiescent, suggesting recent mobilization from the bone marrow, and were capable of differentiating ex vivo. Circulating HSPC numbers were significantly increased during natalizumab, but heterogeneously, allowing the stratification of mobilizer and nonmobilizer subgroups. Nonmobilizer status was associated with persistence of disease activity during treatment. The frequency of B cells and CD103+CD8+ regulatory T cells persistently increased, more significantly in mobilizer patients, who also showed a specific naive/memory B-cell profile. CONCLUSIONS: The data suggest that natalizumab-induced circulating HSPC increase is the result of true mobilization from the bone marrow and has clinical and immunologic relevance. HSPC mobilization, associated with clinical remission and increased proportion of circulating B and regulatory T cells, may contribute to the treatment's mode of action; thus, HSPC blood counts could represent an early biomarker of responsiveness to natalizumab.
OBJECTIVE: To ascertain the mobilization from the bone marrow and the functional relevance of the increased number of circulating hematopoietic stem and progenitor cells (HSPC) induced by the anti-α-4 integrin antibody natalizumab in patients with multiple sclerosis (MS). METHODS: We evaluated CD45(low)CD34+ HSPC frequency by flow cytometry in blood from 45 natalizumab-treated patients (12 of whom were prospectively followed during the first year of treatment as part of a pilot cohort and 16 prospectively followed for validation), 10 untreated patients with MS, and 24 healthy donors. In the natalizumab-treated group, we also assessed sorted HSPC cell cycle status, T- and B-lymphocyte subpopulation frequencies (n = 29), and HSPC differentiation potential (n = 10). RESULTS:Natalizumab-induced circulating HSPC were predominantly quiescent, suggesting recent mobilization from the bone marrow, and were capable of differentiating ex vivo. Circulating HSPC numbers were significantly increased during natalizumab, but heterogeneously, allowing the stratification of mobilizer and nonmobilizer subgroups. Nonmobilizer status was associated with persistence of disease activity during treatment. The frequency of B cells and CD103+CD8+ regulatory T cells persistently increased, more significantly in mobilizer patients, who also showed a specific naive/memory B-cell profile. CONCLUSIONS: The data suggest that natalizumab-induced circulating HSPC increase is the result of true mobilization from the bone marrow and has clinical and immunologic relevance. HSPC mobilization, associated with clinical remission and increased proportion of circulating B and regulatory T cells, may contribute to the treatment's mode of action; thus, HSPC blood counts could represent an early biomarker of responsiveness to natalizumab.
Authors: Spyridon Chalkias; Xin Dang; Evelyn Bord; Marion C Stein; R Philip Kinkel; Jacob A Sloane; Maureen Donnelly; Carolina Ionete; Maria K Houtchens; Guy J Buckle; Stephanie Batson; Igor J Koralnik Journal: Ann Neurol Date: 2014-06-10 Impact factor: 10.422
Authors: R Zivadinov; M G Dwyer; S Hussein; E Carl; C Kennedy; M Andrews; D Hojnacki; M Heininen-Brown; L Willis; M Cherneva; N Bergsland; B Weinstock-Guttman Journal: Mult Scler Date: 2011-12-22 Impact factor: 6.312
Authors: Christian Saure; Clemens Warnke; Fabian Zohren; Thomas Schroeder; Ingmar Bruns; Ron P Cadeddu; Christian Weigelt; Ute Fischer; Guido Kobbe; Hans-Peter Hartung; Ortwin Adams; Bernd C Kieseier; Rainer Haas Journal: Arch Neurol Date: 2011-11
Authors: Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: Elliot M Frohman; Maria Chiara Monaco; Gina Remington; Caroline Ryschkewitsch; Peter N Jensen; Kory Johnson; Molly Perkins; Julia Liebner; Benjamin Greenberg; Nancy Monson; Teresa C Frohman; Daniel Douek; Eugene O Major Journal: JAMA Neurol Date: 2014-05 Impact factor: 18.302
Authors: Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: Alice Laroni; Ilaria Gandoglia; Claudio Solaro; Giuseppe Ribizzi; Tiziana Tassinari; Matteo Pizzorno; Sergio Parodi; Giovanna Baldassarre; Maria Teresa Rilla; Simonetta Venturi; Elisabetta Capello; Maria Pia Sormani; Antonio Uccelli; Giovanni Luigi Mancardi Journal: BMC Neurol Date: 2014-05-12 Impact factor: 2.474
Authors: Galina Gabriely; Andre P da Cunha; Rafael M Rezende; Brendan Kenyon; Asaf Madi; Tyler Vandeventer; Nathaniel Skillin; Stephen Rubino; Lucien Garo; Maria A Mazzola; Panagiota Kolypetri; Amanda J Lanser; Thais Moreira; Ana Maria C Faria; Hans Lassmann; Vijay Kuchroo; Gopal Murugaiyan; Howard L Weiner Journal: Sci Immunol Date: 2017-05-19
Authors: Michelle Naughton; Jill Moffat; George Eleftheriadis; Nira de la Vega Gallardo; Andrew Young; John Falconer; Kristen Hawkins; Ben Pearson; Bernard Perbal; Andrew Hogan; Paul Moynagh; Sam Loveless; Neil P Robertson; Bruno Gran; Rachael Kee; Stella Hughes; Gavin McDonnell; Owain Howell; Denise C Fitzgerald Journal: J Neuroinflammation Date: 2020-11-22 Impact factor: 8.322
Authors: Rui Li; Ayman Rezk; Luke M Healy; Gillian Muirhead; Alexandre Prat; Jennifer L Gommerman; Amit Bar-Or Journal: Front Immunol Date: 2016-01-08 Impact factor: 7.561
Authors: Francesco Marabita; Malin Almgren; Louise K Sjöholm; Lara Kular; Yun Liu; Tojo James; Nimrod B Kiss; Andrew P Feinberg; Tomas Olsson; Ingrid Kockum; Lars Alfredsson; Tomas J Ekström; Maja Jagodic Journal: Sci Rep Date: 2017-11-06 Impact factor: 4.379